236 related articles for article (PubMed ID: 17539747)
1. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.
Tang W
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):407-20. PubMed ID: 17539747
[TBL] [Abstract][Full Text] [Related]
2. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
Tang W; Lu AY
Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation in drug-induced liver injury.
Leung L; Kalgutkar AS; Obach RS
Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
[TBL] [Abstract][Full Text] [Related]
4. Toxicophores: investigations in drug safety.
Williams DP
Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
[TBL] [Abstract][Full Text] [Related]
5. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
Giri S; Nieber K; Bader A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
[TBL] [Abstract][Full Text] [Related]
7. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
[TBL] [Abstract][Full Text] [Related]
8. Selection of new chemical entities with decreased potential for adverse drug reactions.
Park KB; Dalton-Brown E; Hirst C; Williams DP
Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
[TBL] [Abstract][Full Text] [Related]
9. The role of metabolic activation in drug-induced hepatotoxicity.
Park BK; Kitteringham NR; Maggs JL; Pirmohamed M; Williams DP
Annu Rev Pharmacol Toxicol; 2005; 45():177-202. PubMed ID: 15822174
[TBL] [Abstract][Full Text] [Related]
10. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity.
Zhang A; Sun H; Wang P; Han Y; Wang X
Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of potential hepatotoxicity induced by drugs.
Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
[TBL] [Abstract][Full Text] [Related]
12. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
Grillo MP
Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
[TBL] [Abstract][Full Text] [Related]
13. Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
Walgren JL; Mitchell MD; Thompson DC
Crit Rev Toxicol; 2005; 35(4):325-61. PubMed ID: 15989140
[TBL] [Abstract][Full Text] [Related]
14. Predicting toxicities of reactive metabolite-positive drug candidates.
Kalgutkar AS; Dalvie D
Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
[TBL] [Abstract][Full Text] [Related]
15. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
Williams DP; Park BK
Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
Gómez-Lechón MJ; Tolosa L; Donato MT
J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
[TBL] [Abstract][Full Text] [Related]
17. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
Pessayre D; Benhamou JP
C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767
[TBL] [Abstract][Full Text] [Related]
18. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
Zhou S; Chan E; Duan W; Huang M; Chen YZ
Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
[TBL] [Abstract][Full Text] [Related]
19. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
20. Effective Application of Metabolite Profiling in Drug Design and Discovery.
Cerny MA; Kalgutkar AS; Obach RS; Sharma R; Spracklin DK; Walker GS
J Med Chem; 2020 Jun; 63(12):6387-6406. PubMed ID: 32097005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
